Zimmer Biomet
About: Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
Employees: 17,000
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
102% more call options, than puts
Call options by funds: $69.9M | Put options by funds: $34.6M
33% more funds holding in top 10
Funds holding in top 10: 9 [Q4 2024] → 12 (+3) [Q1 2025]
7% more capital invested
Capital invested by funds: $19.2B [Q4 2024] → $20.6B (+$1.42B) [Q1 2025]
0.19% more ownership
Funds ownership: 91.4% [Q4 2024] → 91.59% (+0.19%) [Q1 2025]
3% less funds holding
Funds holding: 1,010 [Q4 2024] → 980 (-30) [Q1 2025]
12% less first-time investments, than exits
New positions opened: 86 | Existing positions closed: 98
25% less repeat investments, than reductions
Existing positions increased: 289 | Existing positions reduced: 385
Research analyst outlook
10 Wall Street Analysts provided 1 year price targets over the past 3 months
10 analyst ratings
Canaccord Genuity William Plovanic | 11%upside $101 | Hold Maintained | 12 May 2025 |
JMP Securities David Turkaly | 37%upside $125 | Market Outperform Maintained | 7 May 2025 |
Goldman Sachs David Roman | 14%upside $104 | Neutral Maintained | 6 May 2025 |
Raymond James Jayson Bedford | 14%upside $104 | Outperform Maintained | 6 May 2025 |
Stifel Rick Wise | 26%upside $115 | Buy Maintained | 6 May 2025 |
Financial journalist opinion
Based on 7 articles about ZBH published over the past 30 days
